KRMD: KORU Medical Company Total Sales

KORU Medical Systems (KRMD) product sales dynamics demonstrate the impact of stringent FDA requirements and device patent protection, confirming the significance of 0.05, which characterizes this valuation parameter. The business relies on its status as a leader in the home immunoglobulin infusion systems sector. High loyalty among chronic patients and the complexity of switching equipment create a sustainable market moat.

KORU Medical Systems Inc. (KRMD) - Company Sales from 07/04/2022 to 11/15/2026

Comprehensive metric breakdowns and analytics for KORU Medical Systems, Inc. (KRMD)

- market value and analyst target forecast:

Market Chart KORU Medical|KRMD - Consensus Target

- market capitalization information:

Market Value KORU Medical Systems Inc.|KRMD - Total Company Value

- book capitalization indicators:

Accounting Value of a Share KORU Medical Systems|KRMD - Company Net Assets|Market Capitalization to Book Value Ratio korumedical.com|KRMD - Aggregate Company Assets

- company liabilities and liquidity data:

- earnings and valuation multiples indicators:

KRMD - Company Net Income|Projected Future Earnings KORU Medical Systems|KRMD - Price to Earnings Ratio|Projected Price to Earnings Ratio korumedical.com|KRMD - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation KORU Medical Systems|KRMD - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) KORU Medical Systems|KRMD - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months korumedical.com|KRMD - Earnings per share growth in current year|Expected earnings per share growth for next year KORU Medical Systems

- issuer revenue and sales details:

KRMD - Revenue and Sales Volume|Company Expected Sales Volume KORU Medical Systems|KRMD - P/S Multiple|Market Cap to Projected Revenue KORU Medical Systems, Inc.

Comprehensive company analysis:KORU Medical Systems Inc. KRMD

KORU Medical Systems is modernizing subcutaneous drug delivery systems by developing its R&D pipeline. The company's total sales revenue trend reflects the effectiveness of smart interface implementation and the expansion of partnerships. This indicator filters out market noise, capturing the actual scale of the business's commercial expansion. Steady growth in this line confirms strengthening market positions, yet signals a risk of overvaluation should demand stagnate. A predictable innovation cycle ensures the company's fundamental stability.

Competing companies